Limits...
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.

Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ - BMC Med (2015)

Bottom Line: It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants.Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF.Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries.

View Article: PubMed Central - PubMed

Affiliation: Southampton Respiratory Biomedical Research Unit, Mailpoint 813, LE75 E Level, South Academic Block, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK. l.richeldi@soton.ac.uk.

ABSTRACT
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the exponentially increasing demand for the enrollment of IPF patients in clinical trials of new drugs is predicted to face a shortage of patients - BRIC countries may thus play a crucial role in advancing towards a cure for IPF.

No MeSH data available.


Related in: MedlinePlus

The mean duration of symptoms in idiopathic pulmonary fibrosis patients at the time of initial diagnosis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4581420&req=5

Fig4: The mean duration of symptoms in idiopathic pulmonary fibrosis patients at the time of initial diagnosis

Mentions: The data indicates that the average number of IPF patients attending a given participating center over 1 year was 49 (range, 10–150 patients). The participating centers were large multispecialty hospitals (attended 38 % of cases), outpatient centers (28 % of cases), and specialized pulmonology centers (50 % of cases). According to interviewed experts, the average age of patients was more than 60 years (67 % of responses). IPF patients in Russia are characterized by male predominance (66 %) with a high prevalence of smokers (61 %). At the time of initial diagnosis of IPF, the average level of forced vital capacity was 50–80 % of predicted values in 78 % of patients and less than 50 % of predicted values in 22 % of patients. The usual duration of symptoms before the diagnosis of IPF was 6–12 months (44 % of responses), 12–18 months (17 % of responses), or more than 24 months (22 % of responses; Fig. 4). Most often, patients with suspected IPF were sent to participating centers by general physicians (56 %), pulmonologists (22 %), and radiologists (22 %). A surgical lung biopsy for confirmation of a diagnosis of IPF was performed, on average, in 20 % of patients (mainly in young patients and in patients with atypical CT imaging). According to the experts’ answers, 89 % of the interviewed experts had the ability to discuss the results of CT scans with radiologists, 89 % of interviewed pulmonologists had the ability to discuss the results of lung biopsies with morphologists, and 77 % of participating centers had the possibility of facilitating a multidisciplinary discussion about IPF cases.Fig. 4


Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.

Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ - BMC Med (2015)

The mean duration of symptoms in idiopathic pulmonary fibrosis patients at the time of initial diagnosis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4581420&req=5

Fig4: The mean duration of symptoms in idiopathic pulmonary fibrosis patients at the time of initial diagnosis
Mentions: The data indicates that the average number of IPF patients attending a given participating center over 1 year was 49 (range, 10–150 patients). The participating centers were large multispecialty hospitals (attended 38 % of cases), outpatient centers (28 % of cases), and specialized pulmonology centers (50 % of cases). According to interviewed experts, the average age of patients was more than 60 years (67 % of responses). IPF patients in Russia are characterized by male predominance (66 %) with a high prevalence of smokers (61 %). At the time of initial diagnosis of IPF, the average level of forced vital capacity was 50–80 % of predicted values in 78 % of patients and less than 50 % of predicted values in 22 % of patients. The usual duration of symptoms before the diagnosis of IPF was 6–12 months (44 % of responses), 12–18 months (17 % of responses), or more than 24 months (22 % of responses; Fig. 4). Most often, patients with suspected IPF were sent to participating centers by general physicians (56 %), pulmonologists (22 %), and radiologists (22 %). A surgical lung biopsy for confirmation of a diagnosis of IPF was performed, on average, in 20 % of patients (mainly in young patients and in patients with atypical CT imaging). According to the experts’ answers, 89 % of the interviewed experts had the ability to discuss the results of CT scans with radiologists, 89 % of interviewed pulmonologists had the ability to discuss the results of lung biopsies with morphologists, and 77 % of participating centers had the possibility of facilitating a multidisciplinary discussion about IPF cases.Fig. 4

Bottom Line: It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants.Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF.Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries.

View Article: PubMed Central - PubMed

Affiliation: Southampton Respiratory Biomedical Research Unit, Mailpoint 813, LE75 E Level, South Academic Block, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK. l.richeldi@soton.ac.uk.

ABSTRACT
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the exponentially increasing demand for the enrollment of IPF patients in clinical trials of new drugs is predicted to face a shortage of patients - BRIC countries may thus play a crucial role in advancing towards a cure for IPF.

No MeSH data available.


Related in: MedlinePlus